Cascorbi I - Search Results

1

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.

Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, Blohmer JU, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr CR, Lorenzen S, Lüftner D, Moehler M, Nöthen MM, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz RD. Wörmann B, et al. Among authors: cascorbi i. Oncol Res Treat. 2020;43(11):628-636. doi: 10.1159/000510258. Epub 2020 Oct 23. Oncol Res Treat. 2020. PMID: 33099551 Free article. Review.

2

Epigenetics in Drug Response.

Cascorbi I, Schwab M. Cascorbi I, et al. Clin Pharmacol Ther. 2016 May;99(5):468-70. doi: 10.1002/cpt.349. Clin Pharmacol Ther. 2016. PMID: 27061003

3

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Cascorbi I, et al. Clin Pharmacol Ther. 2001 Mar;69(3):169-74. doi: 10.1067/mcp.2001.114164. Clin Pharmacol Ther. 2001. PMID: 11240981 Clinical Trial.

4

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.

Hartmann JT, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm MM, Heeger S, Bokemeyer C. Hartmann JT, et al. Among authors: cascorbi i. Invest New Drugs. 2013 Jun;31(3):661-8. doi: 10.1007/s10637-012-9856-0. Epub 2012 Jul 26. Invest New Drugs. 2013. PMID: 22832803 Clinical Trial.

5

Functional gene variants of CYP3A4.

Werk AN, Cascorbi I. Werk AN, et al. Among authors: cascorbi i. Clin Pharmacol Ther. 2014 Sep;96(3):340-8. doi: 10.1038/clpt.2014.129. Epub 2014 Jun 13. Clin Pharmacol Ther. 2014. PMID: 24926778 Review.

6

A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.

Cascorbi I, Brockmöller J, Roots I. Cascorbi I, et al. Cancer Res. 1996 Nov 1;56(21):4965-9. Cancer Res. 1996. PMID: 8895751

7

How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.

Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmöller J. Meisel C, et al. Among authors: cascorbi i. Clin Chem Lab Med. 2000 Sep;38(9):869-76. doi: 10.1515/CCLM.2000.126. Clin Chem Lab Med. 2000. PMID: 11097342 Review.

8

Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.

Brockmöller J, Cascorbi I, Kerb R, Roots I. Brockmöller J, et al. Among authors: cascorbi i. Cancer Res. 1996 Sep 1;56(17):3915-25. Cancer Res. 1996. PMID: 8752158

9

Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1).

Bruhn C, Brockmöller J, Cascorbi I, Roots I, Borchert HH. Bruhn C, et al. Among authors: cascorbi i. Biochem Pharmacol. 1999 Dec 1;58(11):1759-64. doi: 10.1016/s0006-2952(99)00269-5. Biochem Pharmacol. 1999. PMID: 10571250

10

Genotype and phenotype relationship in drug metabolism.

Roots I, Laschinski G, Arjomand-Nahad F, Kirchheiner J, Schwarz D, Brockmöller J, Cascorbi I, Gerloff T. Roots I, et al. Among authors: cascorbi i. Ernst Schering Res Found Workshop. 2007;(59):81-100. doi: 10.1007/978-3-540-49529-1_6. Ernst Schering Res Found Workshop. 2007. PMID: 17117716 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

271 results

Search Page